Hector R Wong1, Christopher J Lindsell. 1. *Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Cincinnati, Ohio †Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio ‡Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Abstract
INTRODUCTION: Selecting participants for research based on their risk is an enrichment strategy with potential for enhancing clinical trials in sepsis. Adult Septic Shock Information and Stratification (ASSIST) is a tool for estimating mortality risk that incorporates a panel of biomarkers, age, lactate, and chronic health status. We assessed the utility of ASSIST as an enrichment strategy in a clinical trial testing the efficacy of a polyclonal antitumor necrosis factor-α fragment antibody (AZD9773) in adults with severe sepsis or septic shock. We hypothesized that the effects of AZD9773 are dependent on baseline mortality risk, as estimated by ASSIST. METHODS: This was a post hoc analysis of a recently completed trial of 300 subjects, randomized to placebo, low-dose AZD9773, or high-dose AZD9773. The study's primary endpoint was number of ventilator-free days. There were 286 subjects with available plasma samples from study entry. We measured the ASSIST biomarkers and assigned each subject to low, intermediate, and high-risk strata based on their ASSIST mortality probability. To mirror the study's original statistical plan, we estimated the least squares mean ventilator-free days for each study arm within risk strata. RESULTS: The effect of study arm within ASSIST-based risk strata was significant (P = 0.017). Within the low-risk group, there was an increase in ventilator-free days for both drug arms. Within the intermediate-risk group, there was an increase in ventilator-free days among those in the low-dose arm, but a decrease in the high-dose arm. Among high-risk patients, there was a decrease of ventilator-free days in both drug arms. Analogous associations were observed when modeling 28-day mortality. CONCLUSIONS: In this study, a beneficial effect of AZD9773 might have been observed if the trial selected low to intermediate-risk patients. ASSIST has the potential to serve as an enrichment tool for sepsis clinical trials.
RCT Entities:
INTRODUCTION: Selecting participants for research based on their risk is an enrichment strategy with potential for enhancing clinical trials in sepsis. Adult Septic Shock Information and Stratification (ASSIST) is a tool for estimating mortality risk that incorporates a panel of biomarkers, age, lactate, and chronic health status. We assessed the utility of ASSIST as an enrichment strategy in a clinical trial testing the efficacy of a polyclonal antitumor necrosis factor-α fragment antibody (AZD9773) in adults with severe sepsis or septic shock. We hypothesized that the effects of AZD9773 are dependent on baseline mortality risk, as estimated by ASSIST. METHODS: This was a post hoc analysis of a recently completed trial of 300 subjects, randomized to placebo, low-dose AZD9773, or high-dose AZD9773. The study's primary endpoint was number of ventilator-free days. There were 286 subjects with available plasma samples from study entry. We measured the ASSIST biomarkers and assigned each subject to low, intermediate, and high-risk strata based on their ASSIST mortality probability. To mirror the study's original statistical plan, we estimated the least squares mean ventilator-free days for each study arm within risk strata. RESULTS: The effect of study arm within ASSIST-based risk strata was significant (P = 0.017). Within the low-risk group, there was an increase in ventilator-free days for both drug arms. Within the intermediate-risk group, there was an increase in ventilator-free days among those in the low-dose arm, but a decrease in the high-dose arm. Among high-risk patients, there was a decrease of ventilator-free days in both drug arms. Analogous associations were observed when modeling 28-day mortality. CONCLUSIONS: In this study, a beneficial effect of AZD9773 might have been observed if the trial selected low to intermediate-risk patients. ASSIST has the potential to serve as an enrichment tool for sepsis clinical trials.
Authors: Jonathan Cohen; Jean-Louis Vincent; Neill K J Adhikari; Flavia R Machado; Derek C Angus; Thierry Calandra; Katia Jaton; Stefano Giulieri; Julie Delaloye; Steven Opal; Kevin Tracey; Tom van der Poll; Eric Pelfrene Journal: Lancet Infect Dis Date: 2015-04-19 Impact factor: 25.071
Authors: Hector R Wong; Sarah J Atkinson; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie C Fitzgerald; Paul A Checchia; Keith Meyer; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Shekhar S Raj; Shira Gertz; Christopher J Lindsell Journal: Crit Care Med Date: 2016-10 Impact factor: 7.598
Authors: Hector R Wong; Christopher J Lindsell; Ville Pettilä; Nuala J Meyer; Simone A Thair; Sari Karlsson; James A Russell; Christopher D Fjell; John H Boyd; Esko Ruokonen; Michael G S Shashaty; Jason D Christie; Kimberly W Hart; Patrick Lahni; Keith R Walley Journal: Crit Care Med Date: 2014-04 Impact factor: 7.598
Authors: Gordon R Bernard; Bruno Francois; Jean-Paul Mira; Jean-Louis Vincent; R Phillip Dellinger; James A Russell; Steven P Larosa; Pierre-Francois Laterre; Mitchell M Levy; Wayne Dankner; Nicola Schmitt; Justin Lindemann; Xavier Wittebole Journal: Crit Care Med Date: 2014-03 Impact factor: 7.598
Authors: Hector R Wong; Keith R Walley; Ville Pettilä; Nuala J Meyer; James A Russell; Sari Karlsson; Michael G S Shashaty; Christopher J Lindsell Journal: Biomarkers Date: 2015-01-12 Impact factor: 2.658
Authors: C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin Journal: N Engl J Med Date: 1996-06-27 Impact factor: 91.245
Authors: Hector R Wong; Shelia Salisbury; Qiang Xiao; Natalie Z Cvijanovich; Mark Hall; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Richard Lin; Thomas P Shanley; Michael T Bigham; Anita Sen; Jeffrey Nowak; Michael Quasney; Jared W Henricksen; Arun Chopra; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Patrick Lahni; Christopher J Lindsell Journal: Crit Care Date: 2012-10-01 Impact factor: 9.097
Authors: Hector R Wong; Scott L Weiss; John S Giuliano; Mark S Wainwright; Natalie Z Cvijanovich; Neal J Thomas; Geoffrey L Allen; Nick Anas; Michael T Bigham; Mark Hall; Robert J Freishtat; Anita Sen; Keith Meyer; Paul A Checchia; Thomas P Shanley; Jeffrey Nowak; Michael Quasney; Arun Chopra; Julie C Fitzgerald; Rainer Gedeit; Sharon Banschbach; Eileen Beckman; Patrick Lahni; Kimberly Hart; Christopher J Lindsell Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240
Authors: Hector R Wong; Scott L Weiss; John S Giuliano; Mark S Wainwright; Natalie Z Cvijanovich; Neal J Thomas; Geoffrey L Allen; Nick Anas; Michael T Bigham; Mark Hall; Robert J Freishtat; Anita Sen; Keith Meyer; Paul A Checchia; Thomas P Shanley; Jeffrey Nowak; Michael Quasney; Arun Chopra; Julie C Fitzgerald; Rainer Gedeit; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Patrick Lahni; Christopher J Lindsell Journal: PLoS One Date: 2014-03-13 Impact factor: 3.240
Authors: Brian J Anderson; Carolyn S Calfee; Kathleen D Liu; John P Reilly; Kirsten N Kangelaris; Michael G S Shashaty; Aili L Lazaar; Andrew I Bayliffe; Robert J Gallop; Todd A Miano; Thomas G Dunn; Erik Johansson; Jason Abbott; Alejandra Jauregui; Thomas Deiss; Kathryn Vessel; Annika Belzer; Hanjing Zhuo; Michael A Matthay; Nuala J Meyer; Jason D Christie Journal: Crit Care Date: 2019-12-09 Impact factor: 9.097